Navigation Links
Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
Date:10/28/2008

subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "suggest"; "may"; or similar statements are forward-looking statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements, except as required by law. Risks and uncertainties include risks associated with the reliability of animal modelling, unforeseen safety issues resulting from the handling of Bacillus anthracis, unforeseen safety issues resulting from the administration of Valortim(R) (MDX-1303) in human subjects, uncertainties related to product manufacturing as well as risks detailed from time to time in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and its quarterly reports on Form 10-Q. Copies of Medarex's public disclosure filings are available from its investor relations department.

Statement on Cautionary Factors for PharmAthene

Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; or similar statements are forward-looking statements. PharmAthene disclaims, however, any intent or obligation to update
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Medarex to Present at Thomas Weisel Partners Healthcare Conference 2007
2. Medarex to Present at the Bear Stearns 20th Annual Healthcare Conference
3. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
4. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
5. Medarex to Present at the UBS Global Life Sciences Conference
6. Medarex Announces Election of Marc Rubin as New Board Member
7. Medarex to Present at the 26th Annual JPMorgan Healthcare Conference
8. Medarex Announces Completion of Sale of Shares in Genmab A/S
9. Medarex to Announce 2007 Fourth Quarter and Year-End Financial Results on Tuesday, February 26, 2008
10. Medarex to Present at the Susquehanna Financial Group Healthcare Conference
11. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014 A long-term ... partial breast irradiation (APBI) via interstitial brachytherapy suggests ... positive lymph nodes could be suitable to receive ... (ASTRO) guidelines place these patients in the "unsuitable" ... the 2014 ASTRO meeting, Beaumont Health System,s ...
(Date:9/17/2014)... PRINCETON, N.J. , Sept. 17, 2014 /PRNewswire/ ... developing targeted therapeutic devices to address infectious disease, cancer ... Sciences, Inc. (ESI), disclosed today that each company will ... Summit. On September 18 th , ... presentation entitled: "Exosomes: A Multiplexed Platform for Clinical Management." ...
(Date:9/17/2014)... 2014 JH Technologies announces ... in Irvine. JH Technologies, a leader in sales ... announced an expanded partnership with Leica Microsystems into the ... image analysis solutions will be featured at the grand ... new showroom facility is located within the JH Technologies ...
(Date:9/17/2014)... Intarcia Therapeutics, Inc. today announced the presentation ... cost and predictability of non-adherence in type 2 diabetes ... the European Association for the Study of Diabetes (EASD). ... Ph.D., of Analysis Group, Inc. presented data from the ... to characterize the prevalence of non-adherence and serial non-adherence, ...
Breaking Biology Technology:Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 2Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 4Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit 2Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit 3JH Technologies displays newest microscope imaging technology at Southern California showroom grand opening 2JH Technologies displays newest microscope imaging technology at Southern California showroom grand opening 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5
... ST. JOSEPH, Mich., July 16 GeneGo, Inc., ... biology and pathway,analysis, today announced that the University ... certified GeneGo Center of Excellence (COE). Miller,School of ... and advanced support. COE will provide a pathway ...
... Cell Therapeutics, Inc.,(CTI) (Nasdaq and MTA: CTIC) ... Patients and Providers Act of 2008, which,includes an ... such as Zevalin(R) (Ibritumomab Tiuxetan), overriding,President Bush,s veto., ... U.S. House of Representatives on,June 24, 2008 and ...
... the ... Treatment of Stuttering, ROANOKE, Va., ... non-profit research and,clinical center ( http://www.stuttering.org ) specializing ... stuttering,therapy with advanced behavioral, electronic and computer technologies that,significantly improve ...
Cached Biology Technology:University of Miami Miller School of Medicine Becomes a GeneGo Center of Excellence 218-Month Extension of Reimbursement Rates for Radioimmunotherapies Becomes Law After Congressional Override of Presidential Veto 218-Month Extension of Reimbursement Rates for Radioimmunotherapies Becomes Law After Congressional Override of Presidential Veto 3Video: New, Advanced Therapy Program Helps People Who Stutter Acquire Fluent Speech 2Video: New, Advanced Therapy Program Helps People Who Stutter Acquire Fluent Speech 3
(Date:9/16/2014)... the Columbia Center for Children,s Environmental Health at the ... demonstrate an association between childhood asthma and prenatal exposure ... household products. Results appear online in the journal ... mothers exposed during pregnancy to higher levels of the ... a 72 percent and 78 percent increase in risk ...
(Date:9/16/2014)... brakes" that time the generation of important cells in ... translate sound waves into electrical signals that are carried ... the arrangement of the cells is disordered, hearing is ... be published in The Journal of Neuroscience ... act as brakes to prevent hair cell generation until ...
(Date:9/16/2014)... species has its own bacterial identity. That,s the conclusion ... institutions who studied the genetic fingerprints of bacteria on ... , "This study demonstrates for the first time that ... ecological strategies possess very different microbial communities on their ... postdoctoral researcher in the UO,s Institute of Ecology and ...
Breaking Biology News(10 mins):Phthalates heighten risk for childhood asthma 2Phthalates heighten risk for childhood asthma 3Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2Microbiome research shows each tree species has a unique bacterial identity 2
... an infectious question about eating at restaurants: How clean ... Pascall found that even when they washed dishes in ... to levels accepted in the Food and Drug Administration's ... and milk—can be safe havens for bacteria when dried ...
... with an overt reaction to toxins that cause oxidative ... health threats. , At the 233rd American Chemical Society ... Tech and the Edward Via Virginia College of Osteopathic ... biosensor prototype and correlations to brain tissue damage. ...
... level have on the activation of the female ... a researcher at the Cognitive Neuroscience Center (CNRS/Université ... from the National Institute of Mental Health (Bethesda, ... the first time, the neural networks involved in ...
Cached Biology News:Manual dishwashing study digs up dirt on dish cleanliness 2Manual dishwashing study digs up dirt on dish cleanliness 3Bacterial response to oxidation studied as toxin barometer 2Bacterial response to oxidation studied as toxin barometer 3The influence of the menstrual cycle on the female brain 2The influence of the menstrual cycle on the female brain 3The influence of the menstrual cycle on the female brain 4
... Software has been optimized for the analysis ... the software to quickly and accurately locate ... of an ELISA plate or each section ... has been customized to incorporate standard ELISA ...
For microscopy...
... description: Humidity wells in the base hold ... humidity and probe hydration around the edges ... the risk of waterbath contamination. This chamber ... waterbaths or hybridisation ovens. Linkage: This CLS ...
... R offers maximum application versatility for ... and cooling. Its active heating/cooling function ... temperature control ranges. Five different thermoblocks, ... test tubes, are available for: 0.5 ...
Biology Products: